Fluvoxamine for the treatment of COVID-19

Michael G. Dodds; Eileen B. Doyle; Angela M. Reiersen; Fran Brown; Craig R. Rayner

doi:10.1016/S2214-109X(22)00006-7

Fluvoxamine for the treatment of COVID-19

Michael G. Dodds, Eileen B. Doyle, Angela M. Reiersen, Fran Brown, Craig R. Rayner

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	e332
Journal	The Lancet Global Health
Volume	10
Issue number	3
DOIs	https://doi.org/10.1016/S2214-109X(22)00006-7
State	Published - Mar 2022

Access to Document

10.1016/S2214-109X(22)00006-7

Cite this

@article{9faaacd135794012aabb642f73810258,

title = "Fluvoxamine for the treatment of COVID-19",

author = "Dodds, {Michael G.} and Doyle, {Eileen B.} and Reiersen, {Angela M.} and Fran Brown and Rayner, {Craig R.}",

note = "Funding Information: MGD, EBD, FB, CRR are employed by Certara. Certara scientific support into the TOGETHER study was funded by the Bill and Melinda Gates Foundation. AMR is a co-applicant on a patent application filed by Washington University for the public use of generic selective serotonin reuptake inhibitors for COVID-19. ",

year = "2022",

month = mar,

doi = "10.1016/S2214-109X(22)00006-7",

language = "English",

volume = "10",

pages = "e332",

journal = "The Lancet Global Health",

issn = "2214-109X",

number = "3",

}

TY - JOUR

T1 - Fluvoxamine for the treatment of COVID-19

AU - Dodds, Michael G.

AU - Doyle, Eileen B.

AU - Reiersen, Angela M.

AU - Brown, Fran

AU - Rayner, Craig R.

N1 - Funding Information: MGD, EBD, FB, CRR are employed by Certara. Certara scientific support into the TOGETHER study was funded by the Bill and Melinda Gates Foundation. AMR is a co-applicant on a patent application filed by Washington University for the public use of generic selective serotonin reuptake inhibitors for COVID-19.

PY - 2022/3

Y1 - 2022/3

UR - http://www.scopus.com/inward/record.url?scp=85124528926&partnerID=8YFLogxK

U2 - 10.1016/S2214-109X(22)00006-7

DO - 10.1016/S2214-109X(22)00006-7

M3 - Letter

C2 - 35180412

AN - SCOPUS:85124528926

SN - 2214-109X

VL - 10

SP - e332

JO - The Lancet Global Health

JF - The Lancet Global Health

IS - 3

ER -

Fluvoxamine for the treatment of COVID-19

Access to Document

Other files and links

Cite this